<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

Written by OncLive on April 14, 2022

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer (CRC), and early results have established the pathway as a prime target for drug development.

Topics: Press Coverage

Comments